Columnar Cell Lesions and Subsequent Breast Cancer Risk: A Nested Case-Control Study

DSpace/Manakin Repository

Columnar Cell Lesions and Subsequent Breast Cancer Risk: A Nested Case-Control Study

Citable link to this page

. . . . . .

Title: Columnar Cell Lesions and Subsequent Breast Cancer Risk: A Nested Case-Control Study
Author: Aroner, Sarah A.; Collins, Laura Christine; Schnitt, Stuart Jay; Connolly, James Leo; Colditz, Graham A.; Tamimi, Rulla May

Note: Order does not necessarily reflect citation order of authors.

Citation: Aroner, Sarah A., Laura C. Collins, Stuart J. Schnitt, James L. Connolly, Graham A. Colditz, and Rulla M. Tamimi. 2010. Columnar cell lesions and subsequent breast cancer risk: A nested case-control study. Breast Cancer Research 12(4): R61.
Full Text & Related Files:
Abstract: Introduction: Histologic and genetic evidence suggests that at least some columnar cell lesions (CCL) of the breast represent precursor lesions in the low-grade breast neoplasia pathway. However, the risk of subsequent breast cancer associated with the presence of CCL in a benign breast biopsy is poorly understood.Methods The authors examined the association between the presence of CCL and subsequent breast cancer risk in a nested case-control study of benign breast disease (BBD) and breast cancer within the Nurses' Health Studies (394 cases, 1,606 controls). Benign breast biopsy slides were reviewed by pathologists and CCL presence assessed. Logistic regression was used to compute odds ratios (ORs) and 95% confidence intervals (CIs) for the association between CCL and breast cancer risk. Results: Women with CCL (140 cases, 448 controls) had an increased risk of breast cancer compared with those without CCL (OR = 1.44, 95% CI: 1.14 to 1.83), although this was attenuated and became non-significant after adjustment for the histologic category of BBD (OR = 1.20, 95% CI: 0.94 to 1.54). CCL presence was associated with the greatest risk of breast cancer for those with nonproliferative BBD (OR = 1.36, 95% CI: 0.79 to 2.37) and the lowest risk for those with atypical hyperplasia (AH) (OR = 1.10, 95% CI: 0.65 to 1.87); however, this apparent heterogeneity in risk across BBD categories was not significant (P for interaction between CCL presence and BBD category = 0.77). Conclusions: These results provide evidence that CCL may be an important marker of breast cancer risk in women with BBD but suggest that CCL do not increase breast cancer risk independently of concurrent proliferative changes in the breast.
Published Version: doi:10.1186/bcr2624
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2949654/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:6514710

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters